- Home
- GTE vs PLX Comparison
GTE vs PLX Comparison
Compare GTE & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTE
- PLX
- Stock Information
- Founded
- GTE 2003
- PLX 1993
- Country
- GTE Canada
- PLX United States
- Employees
- GTE N/A
- PLX N/A
- Industry
- GTE Oil & Gas Production
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GTE Energy
- PLX Health Care
- Exchange
- GTE Nasdaq
- PLX Nasdaq
- Market Cap
- GTE 158.1M
- PLX 164.2M
- IPO Year
- GTE N/A
- PLX 1998
- Fundamental
- Price
- GTE $4.71
- PLX $2.60
- Analyst Decision
- GTE
- PLX Strong Buy
- Analyst Count
- GTE 0
- PLX 1
- Target Price
- GTE N/A
- PLX $15.00
- AVG Volume (30 Days)
- GTE 309.7K
- PLX 792.6K
- Earning Date
- GTE 11-03-2025
- PLX 11-13-2025
- Dividend Yield
- GTE N/A
- PLX N/A
- EPS Growth
- GTE N/A
- PLX N/A
- EPS
- GTE N/A
- PLX 0.08
- Revenue
- GTE $621,677,000.00
- PLX $61,948,000.00
- Revenue This Year
- GTE $5.03
- PLX $14.53
- Revenue Next Year
- GTE N/A
- PLX $75.77
- P/E Ratio
- GTE N/A
- PLX $33.57
- Revenue Growth
- GTE N/A
- PLX 62.79
- 52 Week Low
- GTE $3.34
- PLX $0.99
- 52 Week High
- GTE $8.19
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- GTE 60.82
- PLX 82.14
- Support Level
- GTE $4.20
- PLX $1.52
- Resistance Level
- GTE $4.61
- PLX $2.12
- Average True Range (ATR)
- GTE 0.25
- PLX 0.12
- MACD
- GTE 0.04
- PLX 0.05
- Stochastic Oscillator
- GTE 94.76
- PLX 96.79
About GTE Gran Tierra Energy Inc.
Gran Tierra Energy Inc is an independent energy company. The company, along with its subsidiaries, is focused on oil and gas exploration and production, with assets in Colombia, Canada, and Ecuador. It produces oil, natural gas, and natural gas liquids. Gran Tierra has assembled a diversified, high-quality asset base that is fully operated in Colombia and Ecuador and partly in Canada. The company operates various blocks in Colombia and Ecuador, spanning three basins. It also has contiguous areas in Alberta, Canada, spanning various gross acres across the Western Canadian Sedimentary Basin. The company's reportable segments are Colombia, Ecuador, Canada, and Other. A majority of its revenue is derived from its operations in Colombia.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.